Clinical and metabolomics analysis of hepatocellular carcinoma patients with diabetes mellitus
| Autor: | Hongping Xia, Tian Xie, Ming Shi, Karthik Sekar, Jianxiang Chen, Kam M. Hui |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Liver Cirrhosis Male Oncology China medicine.medical_specialty Carcinoma Hepatocellular Endocrinology Diabetes and Metabolism Clinical Biochemistry Normal tissue 01 natural sciences Biochemistry 03 medical and health sciences Metabolomics Risk Factors Diabetes mellitus Internal medicine Epidemiology Biomarkers Tumor Diabetes Mellitus medicine Humans neoplasms Aged 030304 developmental biology Principal Component Analysis 0303 health sciences business.industry Liver Neoplasms 010401 analytical chemistry Middle Aged medicine.disease Tumor tissue Molecular medicine digestive system diseases 0104 chemical sciences Liver Hepatocellular carcinoma Metabolite profiling Metabolome Female business |
| Zdroj: | Metabolomics. 15 |
| ISSN: | 1573-3890 1573-3882 |
| Popis: | Diabetes and cancer are among the most frequent causes of death worldwide. Recent epidemiological findings have indicated a link between diabetes and cancer in several organs, particularly the liver. A number of epidemiological studies have demonstrated that diabetes is an established independent risk factor for hepatocellular carcinoma (HCC). However, the metabolites connecting diabetes and HCC remains less well understood. The study aimed to identify clinical and metabolomics differences of HCC from patients with/without diabetes using comprehensive global metabolomics analysis. Metabolite profiling was conducted with the Metabolon platform for 120 human diabetes/non-diabetes HCC tumor/normal tissues. Standard statistical analyses were performed using the Partek Genomics Suite on log-transformed data. Principal component analysis (PCA) was conducted using all and dysregulated metabolites. We identified a group of metabolites that are differentially expressed in the tumor tissues of diabetes HCC compared to non-diabetes HCC patients. Meanwhile, we also identified a group of metabolites that are differentially expressed in the matched normal liver tissues of diabetes HCC compared to non-diabetes HCC patients. Some metabolites are consistently dysregulated in the tumor or matched normal tissues of HCC with or without diabetes. However, some metabolites, including 2-hydroxystearate, were only overexpressed in the tumor tissues of HCC with diabetes and associated with the glucose level. Metabolic profiling identifies distinct dysregulated metabolites in HCC patients with/without diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink